Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension

European Journal of Clinical Investigation

Volumn 43, Issue 9, 2013, Pages 926-932

  Eisinger, Kristina ^a   Krautbauer, Sabrina ^a   Wiest, Reiner ^b   Karrasch, Thomas ^a   Hader, Yvonne ^a   Scherer, Marcus N ^a   Farkas, Stefan ^a   Aslanidis, Charalampos ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adipokine; CHILD POUGH stage; Portal vein; Varices

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ARGININE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; N(G),N(G) DIMETHYLARGININE; OMENTIN; UNCLASSIFIED DRUG; UREA;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAABDOMINAL FAT; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTHROMBIN TIME; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UREA BLOOD LEVEL; VARICOSIS;

ADIPOKINE; CHILD-POUGH STAGE; PORTAL VEIN; VARICES;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; ASCITES; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYPERTENSION, PORTAL; KIDNEY; KIDNEY FUNCTION TESTS; LECTINS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PORTAL VEIN; PORTASYSTEMIC SHUNT, SURGICAL; VARICOSE VEINS;

EID: 84881662548     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12122     Document Type: Article

References (36)

1. Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011;25:281-90.
2. Marra F, Navari N, Vivoli E, Galastri S, Provenzano A. Modulation of liver fibrosis by adipokines. Dig Dis 2011;29:371-6.
3. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:273-80.
4. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-61.
5. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011;46:91-7.
6. Zhang YY, Zhou LM. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol 2013;698:137-44.
7. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655-61.
8. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012;686:116-23.
9. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011;408:339-43.
10. Zipprich A. Hemodynamics in the isolated cirrhotic liver. J Clin Gastroenterol 2007;41(Suppl 3):S254-8.
11. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010;393:668-72.
12. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012;287:408-17.
13. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 2012;32:199-213.
14. Wiest R. Splanchnic and systemic vasodilation: the experimental models. J Clin Gastroenterol 2007;41(Suppl 3):S272-87.
15. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006;231:70-5.
16. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004;41:55-9.
17. Mookerjee RP, Vairappan B, Jalan R. The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: the missing piece? Hepatology 2007;46:943-6.
18. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003;22:17-22.
19. Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005;25:1079-90.
20. Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hep Intl 2008;2:416-28.
21. Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165-71.
22. Wanninger J, Weigert J, Wiest R, Bauer S, Karrasch T, Farkas S, et al. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 2011;55:435-40.
23. Wanninger J, Wiest R, Bauer S, Neumeier M, Eisinger K, Farkas S, et al. Portal levels of latent transforming growth factor-beta are related to liver function in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2011;23:218-23.
24. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010;95:1404-11.
25. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010;72:342-8.
26. Wiest R, Weigert J, Wanninger J, Neumeier M, Bauer S, Schmidhofer S, et al. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine 2011;53:178-83.
27. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
28. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008;28:110-22.
29. Wadhawan M, Dubey S, Sharma BC, Sarin SK. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci 2006;51:2264-9.
30. Assadi M, Salimipour H, Akbarzadeh S, Nemati R, Jafari SM, Bargahi A, et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS ONE 2011;6:e24240.
31. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011;32:873-8.
32. Valentini L, Glaser S, Schuetz T, Omar A, Kasim E, Kroencke T, et al. Serum bile acids and leptin interact with glucose metabolism in patients with liver cirrhosis. Clin Nutr 2013;32:122-9.
33. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29-33.
34. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
35. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
36. Siroen MP, Wiest R, Richir MC, Teerlink T, Rauwerda JA, Drescher FT, et al. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J Gastroenterol 2008;14:7214-19.